| Title |
Duration of adjuvant chemotherapy for patients with non‐metastatic colorectal cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, January 2010
|
| DOI | 10.1002/14651858.cd007046.pub2 |
| Pubmed ID | |
| Authors |
Gaëtan Des Guetz, Bernard Uzzan, Jean‐Francois Morere, Gerard Perret, Patrick Nicolas |
| Abstract |
Surgery of primary tumour is the backbone of colorectal cancer treatment (CRC). But in stage III cancer, metastatic or local relapse is often observed (50%). So, adjuvant treatment is always considered in this setting. The best treatment duration of hypothetic disease is not easy to define. Adjuvant chemotherapy for CRC actually lasts 6 months. The choice of optimal duration is based upon old studies using 5-fluorouracil (5FU). During the last ten years, results of major randomized controlled studies (RCTs) comparing different durations of treatments and different schedules in adjuvant setting were published. Several studies compared a 6-month chemotherapy with a longer treatment. Conversely, a single study by Chau et al compared a 6 month chemotherapy with continuous treatment lasting 3 months. But the optimal duration of these chemotherapies could be challenged. Even though the optimal duration of chemotherapy in CRC is a major issue, it has never been answered adequately. |
Mendeley readers
The data shown below were compiled from readership statistics for 88 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 1 | 1% |
| Unknown | 87 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 17 | 19% |
| Student > Master | 11 | 13% |
| Researcher | 9 | 10% |
| Student > Ph. D. Student | 8 | 9% |
| Professor | 5 | 6% |
| Other | 14 | 16% |
| Unknown | 24 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 41 | 47% |
| Agricultural and Biological Sciences | 8 | 9% |
| Nursing and Health Professions | 4 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 3% |
| Engineering | 2 | 2% |
| Other | 6 | 7% |
| Unknown | 24 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 March 2012.
All research outputs
#22,830,981
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#11,281
of 11,842 outputs
Outputs of similar age
#165,899
of 172,589 outputs
Outputs of similar age from Cochrane database of systematic reviews
#111
of 116 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 172,589 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 116 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.